Heliyon (Oct 2023)

Trends of participants in convalescent plasma donation for COVID-19 in Japan as the pandemic evolved

  • Tetsuya Suzuki,
  • Yusuke Asai,
  • Kozue Takahashi,
  • Mio Sanada,
  • Yumiko Shimanishi,
  • Mari Terada,
  • Lubna Sato,
  • Makoto Inada,
  • Gen Yamada,
  • Yutaro Akiyama,
  • Yusuke Oshiro,
  • Katsuyuki Shiratori,
  • Tomiteru Togano,
  • Yuki Takamatsu,
  • Maeda Kenji,
  • Akihiro Matsunaga,
  • Yukihito Ishizaka,
  • Hidetoshi Nomoto,
  • Noriko Iwamoto,
  • Sho Saito,
  • Satoshi Kutsuna,
  • Shinichiro Morioka,
  • Norio Ohmagari

Journal volume & issue
Vol. 9, no. 10
p. e20568

Abstract

Read online

Background: We aimed to investigate chronological changes in the characteristics of participants in a coronavirus disease 2019 convalescent plasma donation study that may benefit optimal collection methods in the future. Methods: Data from a convalescent plasma donation study from April 30, 2020 to November 5, 2021 were collected and analyzed. After August 23, 2021, an interim analysis of factors linked to higher antibody titers led us to restrict our participant recruitment criteria to participants who were within 4 months of disease onset and to patients who were otherwise most likely to have sufficiently high antibody titers. Overall, 1299 samples from 1179 patients were analyzed. Results: Over the duration of the study, 35.9% of the samples were deemed eligible for convalescent plasma collection. The overall eligibility rate initially declined, dipping to 120 days post disease onset increased. After the addition of days from onset and vaccination status to our participant recruitment criteria, the eligibility rate improved significantly. Conclusions: As outbreaks of emerging infectious disease occur, it is desirable to construct and implement a scheme for convalescent plasma donation promptly and to monitor the eligibility rate over time. If it declines, promptly analyze and resolve the associated factors. Additionally, vaccine development and infection prevalence are likely to influence the effective recruitment of participants with high antibody titers.

Keywords